Literature DB >> 6811446

Immunochemical demonstration of an ovarian cancer-associated urinary peptide.

U H Stenman, M L Huhtala, R Koistinen, M Seppälä.   

Abstract

Immunization with a peptide fraction from ovarian cancer urine resulted in an antiserum that reacts with a 6,000 dalton (6K) peptide. In urine from some patients with advanced gynaecological cancer, the concentration of 6K peptide was high enough to be detected by immunodiffusion. By radioimmunoassay the levels in normal serum could be determined. The concentrations in serum was 5-20 microgram/l and that in urine 5-50 microgram/l. Elevated levels were observed in urine from 5 out of 8 patients with ovarian cancer, 10 out of 14 patients with cervical cancer and 9 out of 14 patients with endometrial cancer. The highest level observed was 12,000 microgram/l. High concentrations of the 6K peptide (100-300 microgram/l) were observed in amniotic fluid from 14-16 weeks of pregnancy. Some tumor extracts also had a high concentration of the 6K peptide. No immunological relationship was observed between the peptide and known tumor-associated antigens or serum proteins. These results suggest that the peptide is a new oncodevelopmental peptide which may have significance as a tumor marker.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6811446     DOI: 10.1002/ijc.2910300110

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  Immunoreactive pancreatic secretory trypsin inhibitor in normal, inflammatory and neoplastic gallbladders.

Authors:  H Bohe; M Bohe; C Lindström; K Ohlsson
Journal:  Gastroenterol Jpn       Date:  1991-02

2.  Reaction of a tumour-associated trypsin inhibitor with serine proteinases associated with coagulation and tumour invasion.

Authors:  U Turpeinen; E Koivunen; U H Stenman
Journal:  Biochem J       Date:  1988-09-15       Impact factor: 3.857

3.  Role of the tumor-associated trypsin inhibitor SPINK1 in cancer development.

Authors:  Ulf-Håkan Stenman
Journal:  Asian J Androl       Date:  2011-05-23       Impact factor: 3.285

4.  Appearance mechanism and molecular heterogeneity of serum pancreatic secretory trypsin inhibitor (PSTI).

Authors:  I Nakano; A Funakoshi; T Sumii; K Miyazaki; Y Oogami; T Kimura; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1985-08

5.  Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.

Authors:  P A Pasanen; M Eskelinen; K Partanen; P Pikkarainen; I Penttilä; E Alhava
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  Identification of genes up-regulated in urothelial tumors: the 67-kd laminin receptor and tumor-associated trypsin inhibitor.

Authors:  Christine P Diggle; Sheena Cruickshank; Jonathon D Olsburgh; Stephanie Pellegrin; Barbara Smith; Rosamonde E Banks; Peter J Selby; Margaret A Knowles; Jennifer Southgate; Patricia Harnden
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

7.  Cyst fluid tumor-associated trypsin inhibitor may be helpful in the differentiation of cystic pancreatic lesions.

Authors:  Sari Räty; Juhani Sand; Henrik Alfthan; Caj Haglund; Isto Nordback
Journal:  J Gastrointest Surg       Date:  2004 Jul-Aug       Impact factor: 3.452

8.  Modulation of Gold Nanorod Growth via the Proteolysis of Dithiol Peptides for Enzymatic Biomarker Detection.

Authors:  Matthew N Creyer; Zhicheng Jin; Colman Moore; Wonjun Yim; Jiajing Zhou; Jesse V Jokerst
Journal:  ACS Appl Mater Interfaces       Date:  2021-09-14       Impact factor: 10.383

9.  Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker.

Authors:  Aileen Marshall; Margus Lukk; Claudia Kutter; Susan Davies; Graeme Alexander; Duncan T Odom
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

10.  Role of Intrapancreatic SPINK1/Spink3 Expression in the Development of Pancreatitis.

Authors:  Masaki Ohmuraya; Aki Sugano; Masahiko Hirota; Yutaka Takaoka; Ken-Ichi Yamamura
Journal:  Front Physiol       Date:  2012-05-07       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.